Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glasses aim to stop kids' eyesight from getting worse

NCT ID NCT03623074

Disease control Sponsor: SightGlass Vision, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This 3-year study tests whether a new type of spectacle lens can slow the progression of nearsightedness (myopia) in children aged 6 to 10. A total of 266 kids will wear either the novel lenses or standard lenses, and researchers will measure changes in eye length and prescription strength. The goal is to find a safe, easy way to control myopia without contact lenses or other treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
novel spectacle lens design
What this could lead to
If successful, these lenses could offer a simple, non-invasive way to slow worsening nearsightedness in children, reducing the need for stronger prescriptions.
What could go wrong
This is a mid-stage trial with 266 children, so results may not apply to all. The lenses might not slow myopia significantly, and long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

266 people

The number who actually took part.

Started

Jul 2018

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 10 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children 6-10 years of age (day prior to 10th birthday) at time of informed consent/assent * SER error between -0.75 and -4.50 D * SER power between the two eyes must be less than or equal to 1.50 D * Willingness to participate in the trial for 3 years without content lens wear Exclusion Criteria: * Previous or current use of contact lenses * Previous or current use of bifocals, progressive addition spectacles lenses * Previous or current use of myopia control treatment * Astigmatism worse then -1.25 DC in either eye

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile myopia

Contacts and locations

Locations

  • Advanced Eyecare, PC

    Raytown, Missouri, 64133, United States

  • Center for Ocular Research & Education, School of Optometry, University of Waterloo School of Optometry & Vision Science

    Waterloo, Ontario, N2L 3G1, Canada

  • Dept of Clinical Research, South Shore Eye Care, LLP

    Wantagh, New York, 11793, United States

  • Dunes Eye Consultants

    Dakota Dunes, South Dakota, 57049, United States

  • Eye Associates of Northeast Louisiana (DBA Haik Humble Eye Center) Research Dept

    West Monroe, Louisiana, 71291, United States

  • Golden Optometric Group

    Whittier, California, 90606, United States

  • Kannarr Eye Care

    Pittsburg, Kansas, 66762, United States

  • SUNY School of Optometry

    New York, New York, 10036, United States

  • Sabal Eye Care

    Longwood, Florida, 32779, United States

  • Sacco Eye Group

    Vestal, New York, 13850, United States

  • Total Eye Care

    Memphis, Tennessee, 38119, United States

  • University of Houston College of Optometry

    Houston, Texas, 77204, United States

  • Visual Performance Center

    Pensacola, Florida, 32503, United States

  • William J Bogus, OD, FAAO

    Salt Lake City, Utah, 84106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.